“GLP-1s prevent or treat Alzheimer's and dementia.”
What the evidence shows
The idea had a plausible mechanism (GLP-1 signaling in the brain, reduced neuroinflammation) and some encouraging observational signals — several large database analyses reported that people taking GLP-1 drugs for diabetes or obesity had lower rates of a recorded dementia diagnosis. That made semaglutide a serious candidate to actually slow Alzheimer's, so it was put to the strongest possible test. In March 2026, The Lancet published evoke and evoke+, two large phase-3, randomized, placebo-controlled trials of oral semaglutide (up to 14 mg daily) in adults with early, amyloid-confirmed Alzheimer's. Over 104 weeks, the drug did not slow clinical decline: the change in the primary cognitive-and-function score (CDR-SB) was essentially identical to placebo in both trials (between-group differences of -0.08 and +0.10, both non-significant). The authors' conclusion was blunt — oral semaglutide was not efficacious in slowing progression in early Alzheimer's.
What we still don’t know
A negative result in early Alzheimer's doesn't answer every version of the question. It's still unknown whether GLP-1 drugs do anything for other forms of dementia (such as vascular dementia), whether starting much earlier or treating much longer would matter, or whether the observational "less dementia in users" signal reflects a real protective effect versus confounding (people healthy enough to be prescribed and stay on these drugs differ from those who aren't). Those observational studies can generate hypotheses but can't establish cause and effect — which is exactly why the randomized trials were run.
Why the claim misleads
"Prevents or treats Alzheimer's" promotes a promising mechanism plus a correlation into a proven benefit — and then the actual, definitive trial came back negative for treatment. It's a textbook case of the gap between "being studied" and "shown to work." The honest read: for treating early Alzheimer's, the best evidence says it doesn't help; for preventing dementia, only weak observational hints exist, and those are not a reason to take these drugs for your brain. Decisions about cognitive health belong with a clinician, not a headline about a weight-loss shot.
Graded by The Peptide Era · evidence, not hype